Objective:

To evaluate the cost-effectiveness and clinical applicability of low-cost, deep whole-genome sequencing (WGS) for cancer detection and monitoring.

Approach:

• Research Collaboration: Collaboration between Weill Cornell Medicine, New York Genome Center, and Ultima Genomics to develop a low-cost WGS method with duplex error correction.
• Technology Assessment: Benchmarking Ultima's sequencing platform against standard methods to assess ctDNA detection performance.

Key Findings:

• The new WGS method can detect cancer DNA in blood samples with high sensitivity.
• The platform can potentially monitor chemotherapy effects in normal cells.
• Lower sequencing costs may facilitate the transition from targeted panel diagnostics to more comprehensive genomic approaches.

Interpretation:

Limitations:

• The transition to low-cost genomic technologies in clinical practice requires significant investment and adaptation.
• There is a need for more machines and scientific publications to validate the technology.

Conclusion:

Sources:

• Weill Cornell Medicine
• New York Genome Center